A Phase 1b, Double-Blind, Placebo-Controlled, First-in-Human Study to Evaluate Safety, Tolerability and Pharmacokinetics of a Two-Week Oral Treatment With STP1 in a Subgroup of Patients With Autism Spectrum Disorder
The main purpose of this study is to evaluate safety and tolerability in a subgroup of patients with Autism Spectrum Disorder (ASD). In addition, Pharmacokinetics and Pharmacodynamics, as well as efficacy of STP1 are being explored.
100 Clinical Results associated with MIF x NKCC1 x NKCC2 x PDE10A x PDE11A x PDE3 x PDE4 x SLC12A4 x TLR4
100 Translational Medicine associated with MIF x NKCC1 x NKCC2 x PDE10A x PDE11A x PDE3 x PDE4 x SLC12A4 x TLR4
0 Patents (Medical) associated with MIF x NKCC1 x NKCC2 x PDE10A x PDE11A x PDE3 x PDE4 x SLC12A4 x TLR4